MapLight Therapeutics, Inc.
MPLT evidence brief
What we can confirm
- BioSniper Score:
- 4.0 / 10
- Market Cap:
- $627.5M
- Next Catalyst:
- Phase2_Topline · Dec 31, 2027
What it means
What to watch
Prepared research question
What matters most for MPLT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MPLT
MapLight Therapeutics, Inc. (MPLT) is a clinical-stage biopharmaceutical company developing circuit-specific CNS therapies, with lead programs in schizophrenia and Alzheimer's disease psychosis and a second candidate targeting autism spectrum disorder.
Key risk: Clinical trial failure
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 6 clinical trials · 1 catalyst for MapLight Therapeutics, Inc..
MapLight Therapeutics, Inc. (MPLT) is a clinical-stage biopharmaceutical company developing circuit-specific CNS therapies, with lead programs in schizophrenia and Alzheimer's disease psychosis and a second candidate targeting autism spectrum disorder.
- Cash & equivalents of $71.6M as of 2026-06-30 [sec]
- Net loss of $60.2M for the six months ended 2026-06-30 [sec]
- Shareholders' equity of $348.3M as of 2026-06-30 [sec]
- Lead candidate ML-007C-MA reported positive Phase 2 ZEPHYR topline results in schizophrenia in July 2026 [sec_mda · as of 2026-08-13]
- ML-007C-MA granted FDA Fast Track designation for Alzheimer's disease psychosis in December 2025 [sec · filed 2026-09-18]
What works
- Lead candidate ML-007C-MA achieved positive Phase 2 topline results in schizophrenia (ZEPHYR trial), supporting advancement toward an end-of-Phase 2 meeting with the FDA [sec_mda · as of 2026-08-13]
- ML-007C-MA received FDA Fast Track designation for Alzheimer's disease psychosis, potentially accelerating development [sec · filed 2026-09-18]
- Cash position of $71.6M as of 2026-06-30 is expected to fund operations through 2027 [sec_mda · as of 2026-05-14]
- Second clinical candidate ML-004 showed clinically meaningful improvements in irritability in an adolescent subgroup in the Phase 2 IRIS trial [news · published 2026-08-13]
What to weigh
- Net loss of $60.2M for the six months ended 2026-06-30 reflects ongoing R&D spending without approved products [sec]
- ML-004's Phase 2 IRIS trial results may not support broad registration; company intends to engage FDA in an end-of-Phase 2 meeting to determine next steps [sec · filed 2026-09-18]
- VISTA Phase 2 trial for ML-007C-MA in Alzheimer's disease psychosis is still enrolling, with topline results not expected until second half of 2027 [sec · filed 2026-09-18]
- Company's cash runway estimate depends on assumptions that may prove wrong, and capital could be consumed sooner than expected [sec_mda · as of 2026-05-14]
From the filings
Quoted directly from source documents.
Positive Phase 2 ZEPHYR topline results for ML-007C-MA in schizophrenia
“In July 2026, we announced positive topline results from ZEPHYR, a Phase 2 trial evaluating ML-007C-MA for the treatment of schizophrenia.”
SEC MD&A · August 13, 2026
FDA Fast Track designation for ML-007C-MA in Alzheimer's disease psychosis
“In December 2025, ML-007C-MA was granted Fast Track designation by the FDA for the treatment of hallucinations and delusions associated with ADP.”
SEC filings · September 18, 2026
Catalyst timeline
- 2027-12-31 · Phase2_Topline — MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Risks & what to watch (4)›
Key risks
- Clinical trial failure — ML-007C-MA or ML-004 may fail to meet endpoints in ongoing or future trials, delaying or halting development [sec · filed 2026-09-18]
- Cash burn rate — Net loss of $60.2M in six months; cash runway depends on assumptions that may be wrong [sec_mda · as of 2026-05-14]
- Regulatory uncertainty — End-of-Phase 2 meetings with FDA for both ML-007C-MA and ML-004 may result in requests for additional trials [sec · filed 2026-09-18]
- Single-asset dependence — Lead candidate ML-007C-MA drives near-term value; preclinical programs (ML-009, ML-055, ML-021) are early-stage [sec_mda · as of 2026-03-26]
What to watch
- End-of-Phase 2 meeting with FDA for ML-007C-MA in schizophrenia, expected after ZEPHYR results [sec_mda · as of 2026-08-13]
- Topline results from VISTA Phase 2 trial for ML-007C-MA in Alzheimer's disease psychosis, expected second half of 2027 [sec · filed 2026-09-18]
- End-of-Phase 2 meeting with FDA for ML-004 in autism spectrum disorder, planned after IRIS results [sec · filed 2026-09-18]
- Cash runway and spending rate updates in future quarterly filings [sec · filed 2026-09-18]
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 6, 2026 · How we verify sources →
Run MapLight Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MapLight Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.06 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~443d
6 buys · 117 sells (180d)
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
81
Total value held
$445.0M
| Holder | Shares | Value |
|---|---|---|
| novo holdings a/s | 3,686,622 | $74.9M |
| fcpm iii services b.v. | 3,226,400 | $65.6M |
| goldman sachs group inc | 1,994,873 | $40.6M |
| blackrock, inc. | 1,339,731 | $27.2M |
| blue owl capital holdings lp | 1,005,929 | $20.5M |
| nan fung group holdings ltd | 971,253 | $19.7M |
| 5am venture management, llc | 950,011 | $19.3M |
| sanofi | 912,041 | $18.5M |
| vanguard capital management llc | 719,820 | $14.6M |
| pivotal bioventure partners investment advisor llc | 611,447 | $12.4M |
Showing top 10 of 81 institutional holders of MapLight Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 3.4%
- Days to cover
- 6.2
- Shares short
- 1,418,306
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MPLT short interestGovernance
Frequently asked questions
What is the AI investment thesis for MapLight Therapeutics, Inc.?
MapLight Therapeutics, Inc. (MPLT) is a clinical-stage biopharmaceutical company developing circuit-specific CNS therapies, with lead programs in schizophrenia and Alzheimer's disease psychosis and a second candidate targeting autism spectrum disorder.
What is MapLight Therapeutics, Inc.'s next catalyst?
MapLight Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase2_Topline: MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update" — expected December 31, 2027.
Who is the CEO of MapLight Therapeutics, Inc.?
Dr. Christopher A. Kroeger M.B.A., M.D., Ph.D. is the chief executive officer of MapLight Therapeutics, Inc. (MPLT).
Where is MapLight Therapeutics, Inc. headquartered?
MapLight Therapeutics, Inc. (MPLT) is headquartered in Redwood City, CA, United States.
What therapeutic areas does MapLight Therapeutics, Inc. focus on?
MapLight Therapeutics, Inc. develops therapies across Oncology, Neurology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.